www.fgks.org   »   [go: up one dir, main page]
Skip to main content
SpringerLink
Log in

Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness

Principles and Practice

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Carbamazepine began to be studied in a systematic fashion in the 1970s and became more widely used in the treatment of bipolar disorder in the 1980s. Interest in carbamazepine has been renewed by (i) the recent US FDA approval of a long-acting preparation for the treatment of acute mania; (ii) studies suggesting some efficacy in bipolar depression; and (iii) evidence of prophylactic efficacy in some difficult-to-treat subtypes of bipolar illness. A series of double-blind controlled studies of the drug were conducted at the US National Institute of Mental Health from the mid-1970s to the mid-1990s. This review summarises our experience in the context of the current literature on the clinical efficacy, adverse effects and pharmacokinetic interactions of carbamazepine.

Carbamazepine has an important and still evolving place in the treatment of acute mania and long-term prophylaxis. It may be useful in individuals with symptoms that are not responsive to other treatments and in some subtypes of bipolar disorder that are not typically responsive to a more traditional agent such as lithium. These subtypes might include those patients with bipolar II disorder, dysphoric mania, substance abuse co-morbidity, mood incongruent delusions, and a negative family history of bipolar illness in first-degree relatives. In addition, carbamazepine may be useful in patients who do not adequately tolerate other interventions as a result of adverse effects, such as weight gain, tremor, diabetes insipidus or polycystic ovarian syndrome.

We review our clinical and research experience with carbamazepine alone and in combination with lithium, valproic acid and other agents in complex combination treatment of bipolar illness. More precise clinical and biological predictors and correlates of individual clinical responsiveness to carbamazepine and other mood stabilisers are eagerly awaited.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Table II
Table III
Table IV
Table V

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Ballenger JC, Post RM. Kindling as a model for alcohol withdrawal syndromes. Br J Psychiatry 1978; 133: 1–14

    PubMed  CAS  Google Scholar 

  2. Post RM, Rubinow DR, Ballenger JC. Conditioning, sensitization, and kindling: implications for the course of affective illness. In: Post RM, Ballenger JC, editors. Neurobiology of mood disorders. Baltimore (MD): Williams and Wilkins, 1984: 432–66

    Google Scholar 

  3. Post RM, Uhde TW, Ballenger JC, et al. Carbamazepine, temporal lobe epilepsy, and manic-depressive illness. In: Mendlewicz J, Van Praag HM, editors. Advances in biological psychiatry. Vol. 8: temporal lobe epilepsy, mania, schizophrenia, and the limbic system. Basel: S. Karger AG, 1982: 117–56

    Google Scholar 

  4. Post RM, Uhde TW, Putnam FW, et al. Kindling and carbamazepine in affective illness. J Nerv Ment Dis 1982; 170: 717–31

    PubMed  CAS  Google Scholar 

  5. Albright PS, Burnham WM. Development of a new pharmacological seizure model: effects of anticonvulsants on cortical-and amygdala-kindled seizures in the rat. Epilepsia 1980; 21: 681–9

    PubMed  CAS  Google Scholar 

  6. Babington RG. The pharmacology of kindling. In: Hanin I, Usdin E, editors. Animal models of psychiatry and neurology. Oxford: Pergamon Press, 1977: 141–9

    Google Scholar 

  7. Papez JW. A proposed mechanism of emotion. Arch Neurol Psychiatry 1937; 38: 725–43

    Google Scholar 

  8. MacLean PD. The triune brain in conflict. Psychother Psychosom 1977; 28: 207–20

    PubMed  CAS  Google Scholar 

  9. Marjerrison G, Jedlicki SM, Keogh RP, et al. Carbamazepine: behavioral, anticonvulsant and EEG effects in chronically-hospitalized epileptics. Dis Nerv Syst 1968; 29: 133–6

    PubMed  CAS  Google Scholar 

  10. Penry JK, Daly DD. Complex partial seizures and their treatment: advances in neurology. Vol. 11. New York: Raven Press, 1975

    Google Scholar 

  11. Post RM, Uhde TW. Are the psychotropic effects of carbamazepine in manic-depressive illness mediated through the limbic system? Psychiatr J Univ Ottawa 1985; 10: 205–19

    CAS  Google Scholar 

  12. Dalby MA. Antiepileptic and psychotropic effect of carbamazepine(Tegretol) in the treatment of psychomotor epilepsy. Epilepsia 1971; 12: 325–34

    PubMed  CAS  Google Scholar 

  13. Dalby MA. Behavioral effects of carbamazepine. In: Penry JK, Daly DD, editors. Complex partial seizures and their treatment: advances in neurology. Vol. 11. New York: Raven Press, 1975: 331–43

    Google Scholar 

  14. Okuma T, Kishimoto A, Inoue K, et al. Anti-manic and prophylactic effects of carbamazepine (Tegretol) on manic depressive psychosis: a preliminary report. Folia Psychiatr Neurol Jpn 1973; 27: 283–97

    PubMed  CAS  Google Scholar 

  15. Okuma T, Kishimoto A. A history of investigation on the mood stabilizing effect of carbamazepine in Japan. Psychiatry Clin Neurosci 1998; 52: 3–12

    PubMed  CAS  Google Scholar 

  16. Takezaki H, Hanaoka M. The use of carbamazepine (Tegretol) in the control of manic-depressive psychosis and other manic, depressive states. Clin Psychiatry 1971; 13: 173–82

    Google Scholar 

  17. Ballenger JC, Post RM. Therapeutic effects of carbamazepine in affective illness: preliminary report. Commun Psychopharmacol 1978; 2: 159–75

    PubMed  CAS  Google Scholar 

  18. Ballenger JC, Post RM. Carbamazepine in manic-depressive illness: a new treatment. Am J Psychiatry 1980; 137: 782–90

    PubMed  CAS  Google Scholar 

  19. Post RM, Uhde TW, Ballenger JC, et al. Prophylactic efficacy of carbamazepine in manic-depressive illness. Am J Psychiatry 1983; 140: 1602–4

    PubMed  CAS  Google Scholar 

  20. Post RM, Uhde TW, Roy-Byrne PP, et al. Antidepressant effects of carbamazepine. Am J Psychiatry 1986; 143: 29–34

    PubMed  CAS  Google Scholar 

  21. Post RM, Uhde TW, Roy-Byrne PP, et al. Correlates of anti-manic response to carbamazepine. Psychiatry Res 1987; 21: 71–83

    PubMed  CAS  Google Scholar 

  22. Post RM, Luckenbaugh DA. Unique design issues in clinical trials of patients with bipolar affective disorder. J Psychiatr Res 2003; 37: 61–73

    PubMed  Google Scholar 

  23. Okuma T, Inanaga K, Otsuki S, et al. Comparison of the antimanic efficacy of carbamazepine and chlorpromazine: a double-blind controlled study. Psychopharm 1979; 66: 211–7

    CAS  Google Scholar 

  24. Grossi E, Sacchetti E, Vita A, et al. Carbamazepine vs chlorpromazine in mania: a double-blind trial. In: Emrich HM, Okuma T, Muller AA, editors. Anticonvulsants in affective disorders. Amsterdam: Excerpta Medica, 1984: 177–87

    Google Scholar 

  25. Klein E, Bental E, Lerer B, et al. Carbamazepine and haloperidol vs placebo and haloperidol in excited psychoses. Arch Gen Psychiatry 1984; 41: 165–70

    PubMed  CAS  Google Scholar 

  26. Goncalves N, Stoll KD. Carbamazepine in manic syndromes: a controlled double-blind study. Nervenarzt 1985; 56: 43–7

    PubMed  CAS  Google Scholar 

  27. Lenzi A, Lazzerini F, Grossi E, et al. Use of carbamazepine in acute psychosis: a controlled study. J Int Med Res 1986; 14: 78–84

    PubMed  CAS  Google Scholar 

  28. Stoll KD, Bisson HE, Fischer E, et al. Carbamazepine versus haloperidol in manic syndromes: first report of a multicentric study in Germany. In: Shagass C, Josiassen RC, Bridger WH, et al., editors. Biological Psychiatry 1985. Amsterdam: Elsevier Science Publishing Co. Inc., 1986: 332–4

    Google Scholar 

  29. Desai NG, Gangadhar BN, Channabasavanna SM, et al. Carbamazepine hastens therapeutic action of lithium in mania. Proceedings of the International Conference on New Directions in Affective Disorders. 1987 Apr 5–9; Jerusalem. New York: Springer Verlag, 1987: 97

    Google Scholar 

  30. Lerer B, Moore N, Meyendorff E, et al. Carbamazepine versus lithium in mania: a double-blind study. J Clin Psychiatry 1987; 48: 89–93

    PubMed  CAS  Google Scholar 

  31. Lusznat RM, Murphy DP, Nunn CM. Carbamazepine vs lithium in the treatment and prophylaxis of mania. Br J Psychiatry 1988; 153:198–204

    CAS  PubMed  Google Scholar 

  32. Okuma T, Yamashita I, Takahashi R, et al. A double-blind study of adjunctive carbamazepine versus placebo on excited states of schizophrenic and schizoaffective disorders. Acta Psychiatr Scand 1989; 80: 250–9

    PubMed  CAS  Google Scholar 

  33. Brown D, Silverstone T, Cookson J. Carbamazepine compared to haloperidol in acute mania. Int Clin Psychopharmacol 1989; 4: 229–38

    PubMed  CAS  Google Scholar 

  34. Moller HJ, Kissling W, Riehl T, et al. Double-blind evaluation of the antimanic properties of carbamazepine as a comedication to haloperidol. Prog Neuropsychopharmacol Biol Psych 1989; 13: 127–36

    CAS  Google Scholar 

  35. Okuma T, Yamashita I, Takahashi R, et al. Comparison of the antimanic efficacy of carbamazepine and lithium carbonate by double-blind controlled study. Pharmacopsychiatry 1990; 23: 143–50

    PubMed  CAS  Google Scholar 

  36. Small JG, Klapper MH, Milstein V, et al. Carbamazepine compared with lithium in the treatment of mania. Arch Gen Psychiatry 1991; 48: 915–21

    PubMed  CAS  Google Scholar 

  37. Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 478–84

    PubMed  CAS  Google Scholar 

  38. Weisler RH, Keck Jr PE, Swann AC, et al. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2005; 66: 323–30

    PubMed  CAS  Google Scholar 

  39. Zhang ZJ, Kang WH, Tan QR, et al. Adjunctive herbal medicine with carbamazepine for bipolar disorders: a double-blind, randomized, placebo-controlled study. J Psychiatr Res 2007; 41: 360–9

    PubMed  Google Scholar 

  40. Post RM, Speer AM. A brief history of anticonvulsant use in affective disorders. In: Trimble MR, Schmitz B, editors. Scizures, affective disorders and anticonvulsant drugs. Surrey: Clarius Press, 2002: 53–81

    Google Scholar 

  41. Licht RW. Drug treatment of mania: a critical review. Acta Psychiatr Scand 1998; 97: 387–97

    PubMed  CAS  Google Scholar 

  42. Greil W, Kleindienst N, Erazo N, et al. Differential response to lithium and carbamazepine in the prophylaxis of bipolar disorder. J Clin Psychopharmacol 1998; 18: 455–60

    PubMed  CAS  Google Scholar 

  43. Calabrese JR, Shelton MD, Rapport DJ, et al. A 20-month, double-blind, maintenance study of lithium vs divalproex in rapid cycling bipolar disorder. Am J Psychiatry 2005; 162: 2152–61

    PubMed  Google Scholar 

  44. Post RM, Berrettini WH, Uhde TW, et al. Selective response to the anticonvulsant carbamazepine in manic-depressive illness: a case study. J Clin Psychopharmacol 1984; 4: 178–85

    PubMed  CAS  Google Scholar 

  45. Frye MA, Ketter TA, Leverich GS, et al. The increasing use of polypharmacotherapy for refractory mood disorders: 22 years of study. J Clin Psychiatry 2000; 61: 9–15

    PubMed  CAS  Google Scholar 

  46. Frangou S, Raymont V, Bettany D. The Maudsley bipolar disorder project: a survey of psychotropic prescribing patterns in bipolar I disorder. Bipolar Disord 2002; 4: 378–85

    PubMed  Google Scholar 

  47. Post RM, Speer AM, Leverich GS. Complex combination therapy: the evolution toward rational polypharmacy in lithium-resistant bipolar illness. In: Akiskal HS, Tohen M, editors. Bipolar psychopharmacotherapy: caring for the patient. London: John Wiley & Sons Ltd, 2006: 135–67

    Google Scholar 

  48. Kowatch RA, Sethuraman G, Hume JH, et al. Combination pharmacotherapy in children and adolescents with bipolar disorder. Biol Psychiatry 2003; 53: 978–84

    PubMed  CAS  Google Scholar 

  49. Levine J, Chengappa KN, Brar JS, et al. Psychotropic drug prescription patterns among patients with bipolar I disorder. Bipolar Disord 2000; 2: 120–30

    PubMed  CAS  Google Scholar 

  50. Kowatch RA, Fristad M, Birmaher B, et al. Treatment guidelines for children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2005; 44: 213–35

    PubMed  Google Scholar 

  51. Keck Jr PE, Perlis RH, Otto MW, et al. The expert consensus guideline series: treatment of bipolar disorder 2004. Postgrad Med Special Rep 2004 Dec: 1–120

  52. Post RM, Speer AM, Obrocea GV, et al. Acute and prophylactic effects of anticonvulsants in bipolar depression. Clin Neurosci Res 2002; 2: 228–51

    CAS  Google Scholar 

  53. Hartong EG, Moleman P, Hoogduin CA, et al. Prophylactic efficacy of lithium versus carbamazepine in treatment-naive bipolar patients. J Clin Psychiatry 2003; 64: 144–51

    PubMed  CAS  Google Scholar 

  54. Denicoff KD, Smith-Jackson EE, Disney ER, et al. Comparative prophylactic efficacy of lithium, carbamazepine, and the combination in bipolar disorder. J Clin Psychiatry 1997; 58: 470–8

    PubMed  CAS  Google Scholar 

  55. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392–400

    PubMed  CAS  Google Scholar 

  56. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013–24

    PubMed  CAS  Google Scholar 

  57. Ketter TA, Calabrese JR. Stabilization of mood from below versus above baseline in bipolar disorder: a new nomenclature. J Clin Psychiatry 2002; 63: 146–51

    PubMed  Google Scholar 

  58. Post RM, Altshuler LL. Mood disorders: treatment of bipolar disorders. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. Philadelphia (PA): Lippincott Williams & Wilkins, 2005: 1661–707

    Google Scholar 

  59. Hogan RE, Garnett WR, Thadani VM. Tolerability and effects on quality of life of twice-daily extended-release carbamazepine in adults with seizure disorders: an open-label, 12- to 36-month continuation study. Clin Ther 2003; 25: 2586–96

    PubMed  CAS  Google Scholar 

  60. Post RM. Extended-release carbamazepine: targeting acute bipolar mania. Curr Psychiatry 2005; 4: 72–80

    Google Scholar 

  61. Post RM, Weiss SR, Chuang DM. Mechanisms of action of anticonvulsants in affective disorders: comparisons with lithium. J Clin Psychopharmacol 1992; 12: 23–35S

    Google Scholar 

  62. Post RM, Chalecka-Franaszek E, Hough C. Mechanisms of action of anticonvulsants and new mood stabilizers. In: Soares JC, Gershon S, editors. Handbook of medical psychiatry. New York: Marcel Dekker, 2003: 767–91

    Google Scholar 

  63. Post RM, Chuang D-M. Mechanism of action of lithium: comparison and contrast with carbamazepine. In: Birch NJ, editor. Lithium and the cell: pharmacology and biochemistry. London: Academic Press, 1991: 199–241

    Google Scholar 

  64. Post RM, Weiss SRB, Chuang D-M, et al. Mechanisms of action of carbamazepine in seizure and affective disorders. In: Joffe RT, Calabrese JR, editors. Anticonvulsants in mood disorders. New York: Marcel Dekker, Inc., 1994: 43–92

    Google Scholar 

  65. Post RM, Weiss SRB, Clark M, et al. Lithium, carbamazepine, and valproate in affective illness: biochemical and neurobiological mechanisms. In: Manji H, Bowden CL, Belmaker RH, editors. Bipolar medications: mechanisms of action. Washington,DC: American Psychiatric Press, 2000: 219–48

    Google Scholar 

  66. Post RM, Leverich GS, Rosoff AS, et al. Carbamazepine prophylaxis in refractory affective disorders: a focus on long-term follow-up. J Clin Psychopharmacol 1990; 10: 318–27

    PubMed  CAS  Google Scholar 

  67. Weiss SR, Clark M, Rosen JB, et al. Contingent tolerance to the anticonvulsant effects of carbamazepine: relationship to loss of endogenous adaptive mechanisms. Brain Res Brain Res Rev 1995; 20: 305–25

    PubMed  CAS  Google Scholar 

  68. Post RM. Prophylaxis of bipolar affective disorders. Intl Rev Psych 1990; 2: 277–320

    Google Scholar 

  69. Post RM, Frye MA, Denicoff KD, et al. Anticonvulsants in the long-term prophylaxis of depression. In: Honig A, Van Praag HM, editors. Depression: neurobiological, psychopathological and therapeutic advances. Sussex: John Wiley & Sons, 1997: 483–98

    Google Scholar 

  70. Pazzaglia PJ, Post RM. Contingent tolerance and reresponse to carbamazepine: a case study in a patient with trigeminal neuralgia and bipolar disorder. J Neuropsychiatry Clin Neurosci 1992; 4: 76–81

    PubMed  CAS  Google Scholar 

  71. Post RM, Weiss SRB. Convergences in course of illness and treatments of the epilepsies and recurrent affective disorders. Clin Electroencephalogr 2004; 35: 14–24

    Google Scholar 

  72. Post RM, Uhde TW, Ballenger JC, et al. Carbamazepine and its -10,11-epoxide metabolite in plasma and CSF: relationship to antidepressant response. Arch Gen Psychiatry 1983; 40: 673–6

    PubMed  CAS  Google Scholar 

  73. Post RM, Uhde TW, Wolff EA. Profile of clinical efficacy and side effects of carbamazepine in psychiatric illness: relationship to blood and CSF levels of carbamazepine and its 10,11-epoxide metabolite. Acta Psychiatr Scand 1984; 69: 104–20

    Google Scholar 

  74. Ketter TA, Pazzaglia PJ, Post RM. Synergy of carbamazepine and valproic acid in affective illness: case report and review of the literature. J Clin Psychopharmacol 1992; 12: 276–81

    PubMed  CAS  Google Scholar 

  75. Ketter TA, Wang PW, Post RM. Carbamazepine and oxcar-bazepine. In: Schatzberg AF, Nemeroff CB, editors. Textbook of psychopharmacology. Washington, DC: American Psychiatric Press, 2004: 581–606

    Google Scholar 

  76. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995; 15: 387–98

    PubMed  CAS  Google Scholar 

  77. Lammers MW, Hekster YA, Keyser A, et al. Neither dosage nor serum levels of antiepileptic drugs are predictive for efficacy and adverse effects. Pharm World Sci 1995; 17: 201–6

    PubMed  CAS  Google Scholar 

  78. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide: an update. Clin Pharmacokinet 1986; 11: 177–98

    PubMed  CAS  Google Scholar 

  79. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine: part I. J Clin Psychopharmacol 1991; 11: 198–203

    PubMed  CAS  Google Scholar 

  80. Ketter TA, Post RM, Worthington K. Principles of clinically important drug interactions with carbamazepine: part II. J Clin Psychopharmacol 1991; 11: 306–13

    PubMed  CAS  Google Scholar 

  81. Ketter TA, Frye MA, Cora-Locatelli G, et al. Metabolism and excretion of mood stabilizers and new anticonvulsants. Cell Mol Neurobiol 1999; 19: 511–32

    PubMed  CAS  Google Scholar 

  82. Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999; 19: 310–5

    PubMed  CAS  Google Scholar 

  83. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania: international, double-blind, randomised controlled trial. Br J Psychiatry 2003; 182: 141–7

    PubMed  Google Scholar 

  84. Crawford P. Interactions between antiepileptic drugs and hormonal contraception. CNS Drugs 2002; 16: 263–72

    PubMed  CAS  Google Scholar 

  85. Kramlinger KG, Phillips KA, Post RM. Rash complicating carbamazepine treatment. J Clin Psychopharmacol 1994; 14: 408–13

    PubMed  CAS  Google Scholar 

  86. Ketter TA, Kalali AH, Weisler RH. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry 2004; 65: 668–73

    PubMed  CAS  Google Scholar 

  87. Vick NA. Suppression of carbamazepine-induced skin rash with prednisone [letter]. N Engl J Med 1983; 309: 1193–4

    PubMed  CAS  Google Scholar 

  88. Murphy JM, Mashman J, Miller JD, et al. Suppression of carbamazepine-induced rash with prednisone. Neurology 1991; 41: 144–5

    PubMed  CAS  Google Scholar 

  89. Coombes BW. Stevens-Johnson syndrome associated with carbamazepine (Tegretol). Med J Aust 1965; 1: 895–6

    Google Scholar 

  90. Rose SJ. Severe hypersensitivity secondary to extended carbamazepine administration [letter]. Clin Pharm 1985; 4: 19, 23

    PubMed  CAS  Google Scholar 

  91. Sobotka JL, Alexander B, Cook BL. A review of carbamazepine’ s hematologic reactions and monitoring recommendations. DICP 1990; 24: 1214–9

    PubMed  CAS  Google Scholar 

  92. Joffe RT, Post RM, Roy-Byrne PP, et al. Hematological effects of carbamazepine in patients with affective illness. Am J Psychiatry 1985; 142: 1196–9

    PubMed  CAS  Google Scholar 

  93. Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: hematological and thyroid effects. Am J Psychiatry 1990; 147: 615–20

    PubMed  CAS  Google Scholar 

  94. Boggs DR, Joyce RA. The hematopoietic effects of lithium. Semin Hematol 1983; 20: 129–38

    PubMed  CAS  Google Scholar 

  95. Gram L, Bentsen KD. Hepatic toxicity of antiepileptic drugs: a review. Acta Neurol Scand Suppl 1983; 97: 81–90

    PubMed  CAS  Google Scholar 

  96. Van Amelsvoort T, Bakshi R, Devaux CB, et al. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia 1994; 35: 181–8

    PubMed  Google Scholar 

  97. Uhde TW, Post RM. Effects of carbamazepine on serum electrolytes: clinical and theoretical implications. J Clin Psychopharmacol 1983; 3: 103–6

    PubMed  CAS  Google Scholar 

  98. Joffe RT, Post RM, Uhde TW. Effects of carbamazepine on serum electrolytes in affectively ill patients. Psychol Med 1986; 16: 331–5

    PubMed  CAS  Google Scholar 

  99. Brewerton TD, Jackson CW. Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. J Clin Psychiatry 1994; 55: 249–51

    PubMed  CAS  Google Scholar 

  100. Vieweg V, Glick JL, Herring S, et al. Absence of carbamazepine-induced hyponatremia among patients also given lithium. Am J Psychiatry 1987; 144: 943–7

    PubMed  CAS  Google Scholar 

  101. Gold PW, Robertson GL, Ballenger JC, et al. Carbamazepine diminishes the sensitivity of the plasma arginine vasopressin response to osmotic stimulation. J Clin Endocrinol Metab 1983; 57: 952–7

    PubMed  CAS  Google Scholar 

  102. Forrest Jr JN, Cohen AD, Torretti J, et al. On the mechanism of lithium-induced diabetes insipidus in man and the rat. J Clin Invest 1974; 53: 1115–23

    PubMed  PubMed Central  CAS  Google Scholar 

  103. Brown DW, Ketter TA, Crumlish J, et al. Carbamazepine-induced increases in total serum cholesterol: clinical and theoretical implications. J Clin Psychopharmacol 1992; 12: 431–7

    PubMed  CAS  Google Scholar 

  104. O’Neill B, Callaghan N, Stapleton M, et al. Serum elevation of high density lipoprotein (HDL) cholesterol in epileptic patients taking carbamazepine or phenytoin. Acta Neurol Scand 1982; 65: 104–9

    PubMed  Google Scholar 

  105. Bramswig S, Sudhop T, Luers C, et al. Lipoprotein(a) concentration increases during treatment with carbamazepine. Epilepsia 2003; 44: 457–60

    PubMed  CAS  Google Scholar 

  106. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989; 320: 1661–6

    PubMed  CAS  Google Scholar 

  107. Rosa FW. Spina bifida in infants of women treated with carbamazepine during pregnancy. N Engl J Med 1991; 324: 674–7

    PubMed  CAS  Google Scholar 

  108. Sitland-Marken PA, Rickman LA, Wells BG, et al. Pharmacologic management of acute mania in pregnancy. J Clin Psychopharmacol 1989; 9: 78–87

    PubMed  CAS  Google Scholar 

  109. Froescher W, Eichelbaum M, Niesen M, et al. Carbamazepine levels in breast milk. Ther Drag Monit 1984; 6: 266–71

    CAS  Google Scholar 

  110. Kuhnz W, Jager-Roman E, Rating D, et al. Carbamazepine and carbamazepine-10,11-epoxide during pregnancy and postnatal period in epileptic mothers and their nursed infants: pharma-cokinetics and clinical effects. Pediatric Pharmacol 1983; 3: 199–208

    CAS  Google Scholar 

  111. Pynnonen S, Kanto J, Sillanpaa M, et al. Carbamazepine: placental transport, tissue concentrations in foetus and newborn, and level in milk. Acta Pharmacol Toxicol (Copenh) 1977; 41: 244–53

    CAS  Google Scholar 

  112. Shimoyama R, Ohkubo T, Sugawara K. Monitoring of carbamazepine and carbamazepine 10,11-epoxide in breast milk and plasma by high-performance liquid chromatography. Ann Clin Biochem 2000; 37: 210–5

    PubMed  CAS  Google Scholar 

  113. Frey B, Braegger CP, Ghelfi D. Neonatal cholestatic hepatitis from carbamazepine exposure during pregnancy and breast feeding. Ann Pharmacother 2002; 36: 644–7

    PubMed  Google Scholar 

  114. Post RM. Valproate use in psychiatry: a focus on bipolar illness. In: Loscher W, editor. Valproate. Basel: Birkhauser Verlag, 1999: 167–201

    Google Scholar 

  115. Post RM, Frye MA. Carbamazepine. In: Sadock BJ, Sadock VA, editors. Kaplan & Sadock’s comprehensive textbook of psychiatry. Philadelphia (PA): Lippincott Williams & Wilkins, 2005: 2732–46

    Google Scholar 

  116. Calabrese JR, Vieta E, Shelton MD. Latest maintenance data on lamotrigine in bipolar disorder. Eur Neuropsychopharmacol 2003; 13 Suppl. 2: 57–66

    Google Scholar 

  117. Mattson RH, Cramer JA, Collins JF. A comparison of valproate with carbamazepine for the treatment of complex partial seizures and secondarily generalized tonic-clonic seizures in adults. The Department of Veterans Affairs Epilepsy Cooperative Study No. 264 Group. N Engl J Med 1992; 327: 765–71

    PubMed  CAS  Google Scholar 

  118. Joffe RT, Post RM, Uhde TW. Effect of carbamazepine on body weight in affectively ill patients. J Clin Psychiatry 1986; 47: 313–4

    PubMed  CAS  Google Scholar 

  119. Denicoff KD, Smith-Jackson EE, Bryan AL, et al. Valproate prophylaxis in a prospective clinical trial of refractory bipolar disorder. Am J Psychiatry 1997; 154: 1456–8

    PubMed  CAS  Google Scholar 

  120. Rasgon N. The relationship between polycystic ovary syndrome and antiepileptic drags: a review of the evidence. J Clin Psychopharmacol 2004; 24: 322–34

    PubMed  Google Scholar 

  121. Isojarvi JI, Tauboll E, Tapanainen JS, et al. On the association between valproate and polycystic ovary syndrome: a response and an alternative view. Epilepsia 2001; 42: 305–10

    PubMed  CAS  Google Scholar 

  122. O’Donovan C, Kusumakar V, Graves GR, et al. Menstrual abnormalities and polycystic ovary syndrome in women taking valproate for bipolar mood disorder. J Clin Psychiatry 2002; 63: 322–30

    PubMed  Google Scholar 

  123. Rasgon NL, Altshuler LL, Fairbanks L, et al. Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord 2005; 7: 246–59

    PubMed  Google Scholar 

  124. MacPhee GJ, Larkin JG, Butler E. Circulating hormones and pituitary responsiveness in young epileptic men receiving long-term antiepileptic medication. Epilepsia 1988; 29: 468–75

    PubMed  CAS  Google Scholar 

  125. Morrell MJ. Reproductive and metabolic disorders in women with epilepsy. Epilepsia 2003; 44 Suppl. 4: 11–20

    Google Scholar 

  126. Brodie MJ, Richens A, Yuen AW. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Lancet 1995; 345: 476–9

    PubMed  CAS  Google Scholar 

  127. Frye MA, Ketter TA, Kimbrell TA, et al. A placebo-controlled study of lamotrigine and gabapentin monotherapy in refractory mood disorders. J Clin Psychopharmacol 2000; 20: 607–14

    PubMed  CAS  Google Scholar 

  128. Yang JD, Elphick M, Sharpley AL, et al. Effects of carbamazepine on sleep in healthy volunteers. Biol Psychiatry 1989; 26: 324–8

    PubMed  CAS  Google Scholar 

  129. Drake ME, Pakalnis A, Bogner JE, et al. Effects of antiepileptic drug monotherapy on nocturnal sleep. Epilepsia 1988; 29: 687

    Google Scholar 

  130. Lipper S, Davidson JRT, Grady TA, et al. Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 1986; 27: 849–54

    PubMed  CAS  Google Scholar 

  131. Marangell LB, George MS, Bissette G, et al. Carbamazepine increases cerebrospinal fluid thyrotropin-releasing hormone levels in affectively ill patients. Arch Gen Psychiatry 1994; 51: 625–8

    PubMed  CAS  Google Scholar 

  132. Strandjord RE, Aanderad S, Myking OL, et al. Influence of carbamazepine on serum thyroxine and triiodothyronine in patients with epilepsy. Acta Neurol Scand 1981; 63: 111–21

    PubMed  CAS  Google Scholar 

  133. Joffe RT, Gold PW, Uhde TW, et al. The effects of carbamazepine on the thyrotropin response to thyrotropin-releasing hormone. Psychiatry Res 1984; 12: 161–6

    PubMed  CAS  Google Scholar 

  134. Roy-Byrne PP, Joffe RT, Uhde TW, et al. Carbamazepine and thyroid function in affectively ill patients. Clinical and theoretical implications. Arch Gen Psychiatry 1984; 41: 1150–3

    PubMed  CAS  Google Scholar 

  135. Post RM, Rubinow DR, Uhde TW, et al. Dopaminergic effects of carbamazepine. Relationship to clinical response in affective illness. Arch Gen Psychiatry 1986; 43: 392–6

    PubMed  CAS  Google Scholar 

  136. Silberman EK, Post RM, Nurnberger J, et al. Transient sensory, cognitive and affective phenomena in affective illness: a comparison with complex partial epilepsy. Br J Psychiatry 1985; 146: 81–9

    PubMed  CAS  Google Scholar 

  137. Ali SO, Denicoff KD, Ketter TA, et al. Psychosensory symptoms in bipolar disorder. Neuropsychiatry Neuropsychol Behav Neurol 1997; 10: 223–31

    PubMed  CAS  Google Scholar 

  138. Hayes SG, Goldsmith BK. Psychosensory symptomatology in anticonvulsant-responsive psychiatric illness. Ann Clin Psychiatry 1991; 3: 27–35

    Google Scholar 

  139. Hough C, Chuang DM. Carbamazepine acts through the peripheral benzodiazepine receptor to up-regulate β-adrenergic receptor mRNA. Soc Neurosci Abstracts 1995; 21: 1145

    Google Scholar 

  140. Montezinho LP, Castro MM, Duarte CB, et al. The interaction between dopamine D2-like and beta-adrenergic receptors in the prefrontal cortex is altered by mood-stabilizing agents. J Neurochem 2006; 96: 1336–48

    PubMed  CAS  Google Scholar 

  141. Rubinow DR, Post RM, Gold PW, et al. Effect of carbamazepine on mean urinary free cortisol excretion in patients with major affective illness. Psychopharmacology (Berl) 1986; 88: 115–8

    CAS  Google Scholar 

  142. Osuch EA, Cora-Locatelli G, Frye MA, et al. Post-dexamethasone cortisol correlates with severity of depression before and during carbamazepine treatment in women but not men. Acta Psychiatr Scand 2001; 104: 397–401

    PubMed  CAS  Google Scholar 

  143. Ketter TA, Kimbrell TA, George MS, et al. Baseline cerebral hypermetabolism associated with carbamazepine response, and hyponietabolism with nimodipine response in mood disorders. Biol Psychiatry 1999; 46: 1364–74

    PubMed  CAS  Google Scholar 

  144. Grof P, Duffy A, Cavazzoni P, et al. Is response to prophylactic lithium a familial trait? J Clin Psychiatry 2002; 63: 942–7

    PubMed  CAS  Google Scholar 

  145. Frye MA, Altshuler LL, McElroy SL, et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry 2003; 160: 883–9

    PubMed  Google Scholar 

  146. Malcolm R, Myrick H, Roberts J, et al. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med 2002; 17: 349–55

    PubMed  PubMed Central  CAS  Google Scholar 

  147. Ballenger JC, Post RM. Carbamazepine in alcohol withdrawal syndromes and schizophrenic psychoses. Psychopharmacol Bull 1984; 20: 572–84

    PubMed  CAS  Google Scholar 

  148. Stuppaeck CH, Pycha R, Miller C, et al. Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 1992; 27: 153–8

    PubMed  CAS  Google Scholar 

  149. Chu NS. Carbamazepine: prevention of alcohol withdrawal seizures. Neurol 1979; 29: 1397–401

    CAS  Google Scholar 

  150. Malcolm R, Myrick H, Roberts J, et al. The differential effects of medication on mood, sleep disturbance, and work ability in outpatient alcohol detoxification. Am J Addict 2002; 11: 141–50

    PubMed  Google Scholar 

  151. Kleindienst N, Greil W. Differential efficacy of lithium and carbamazepine in the prophylaxis of bipolar disorder: results of the MAP study. Neuropsychobiology 2000; 42 Suppl. 1: 2–10

    Google Scholar 

  152. Okuma T, Yamashita I, Takahashi R, et al. Clinical efficacy of carbamazepine in affective, schizoaffective, and schizophrenic disorders. Pharmacopsychiatry 1989; 22: 47–53

    PubMed  CAS  Google Scholar 

  153. Post RM, Uhde TW. Anticonvulsants in non-epileptic psychosis. In: Trimble MR, Bolwig TG, editors. Aspects of epilepsy and psychiatry. Chichester: John Wiley and Sons, 1986: 177–212

    Google Scholar 

  154. Carpenter Jr WT, Kurz R, Kirkpatrick B, et al. Carbamazepine maintenance treatment in outpatient schizophrenics. Arch Gen Psychiatry 1991; 48: 69–72

    PubMed  Google Scholar 

  155. Nachshoni T, Levin Y, Levy A, et al. A double-blind trial of carbamazepine in negative symptom schizophrenia. Biol Psychiatry 1994; 35: 22–6

    PubMed  CAS  Google Scholar 

  156. Yassa R, Dupont D. Carbamazepine in the treatment of aggressive behavior in schizophrenic patients: a case report. Can J Psychiatry 1983; 28: 566–8

    PubMed  CAS  Google Scholar 

  157. Patterson JF. Carbamazepine for assaultive patients with organic brain disease. Psychosomatics 1987; 28: 579–81

    PubMed  CAS  Google Scholar 

  158. Patterson JF. A preliminary study of carbamazepine in the treatment of assaultive patients with dementia. J Geriatr Psychiatry Neurol 1988; 1: 21–3

    PubMed  CAS  Google Scholar 

  159. Fichtner CG, Kuhlman DT, Gruenfeld MJ, et al. Decreased episodic violence and increased control of dissociation in a carbamazepine-treated case of multiple personality. Biol Psychiatry 1990; 27: 1045–52

    PubMed  CAS  Google Scholar 

  160. Coons PM. The use of carbamazepine for episodic violence in multiple personality disorder and dissociative disorder not otherwise specified: two additional cases. Biol Psychiatry 1992; 32: 717–20

    PubMed  CAS  Google Scholar 

  161. Keck PEJ, McElroy SL, Friedman LM. Valproate and carbamazepine in the treatment of panic and posttraumatic stress disorders, withdrawal states, and behavioral dyscontrol syndromes. J Clin Psychopharmacol 1992; 12: 36–41S

    Google Scholar 

  162. Brady KT, Sonne SC, Malcolm RJ, et al. Carbamazepine in the treatment of cocaine dependence: subtyping by affective disorder. Exp Clin Psychopharmacol 2002; 10: 276–85

    PubMed  CAS  Google Scholar 

  163. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry 2003; 60: 1079–88

    PubMed  CAS  Google Scholar 

  164. Calabrese JR, Keck Jr PE, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 2005; 162: 1351–60

    PubMed  Google Scholar 

  165. March JS, Silva SG, Compton S, et al. The case for practical clinical trials in psychiatry. Am J Psychiatry 2005; 162: 836–46

    PubMed  Google Scholar 

  166. Brodie MJ, Kwan P. The star systems: overview and use in determining antiepileptic drug choice. CNS Drugs 2001; 15: 1–12

    PubMed  CAS  Google Scholar 

  167. Post RM, Ketter TA, Denicoff K, et al. Assessment of anticonvulsant drugs in patients with bipolar affective illness. In: Hindmarch I, Stonier PD, editors. Human psychopharmacology: methods and measures. Chichester: John Wiley & Sons, 1993: 211–45

    Google Scholar 

  168. Obrocea GV, Dunn RM, Frye MA, et al. Clinical predictors of response to lamotrigine and gabapentin monotherapy in refractory affective disorders. Biol Psychiatry 2002; 51: 253–60

    PubMed  CAS  Google Scholar 

  169. Post RM, Kowatch RA. The heath care crisis of childhood onset bipolar illness: some recommendations for its amelioration. J Clin Psychiatry 2006; 67: 115–25

    PubMed  Google Scholar 

  170. Kowatch RA, Suppes T, Carmody TJ, et al. Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry 2000; 39: 713–20

    PubMed  CAS  Google Scholar 

  171. Wagner KD, Kowatch RA, Emslie GJ, et al. A double-blind, randomised, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescents. Am J Psychiatry 2006; 163(7): 1179–86

    PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported (in part) by the Intramural Research Program of the NIH, National Institutes of Mental Health.

Thomas Uhde has no conflicts of interest that are directly relevant to the content of this review. Robert Post and James Ballenger have received honoraria and consultancies from several pharmaceutical companies including Shire, GlaxoSmithKline, Bristol Myers Squibb, AstraZeneca and Abbott. Terence Ketter has received honoraria, consultancies and grants from a number of pharmaceutical companies including Shire.

Author information

Authors and Affiliations

  1. Bipolar Collaborative Network, Chevy Chase, Maryland, USA

    Robert M. Post

  2. Penn State School of Medicine, Hershey, Pennsylvania, USA

    Robert M. Post

  3. Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, 401 Quarry Road, Room 2124, Stanford, California, 94305-5723, USA

    Terence A. Ketter

  4. Department of Psychiatry, Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA

    Thomas Uhde

  5. Department of Psychiatry, Medical University of South Carolina, Charleston, South Carolina, USA

    James C. Ballenger

Authors
  1. Robert M. Post
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Terence A. Ketter
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Thomas Uhde
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. James C. Ballenger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Terence A. Ketter.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Post, R.M., Ketter, T.A., Uhde, T. et al. Thirty Years of Clinical Experience with Carbamazepine in the Treatment of Bipolar Illness. CNS Drugs 21, 47–71 (2007). https://doi.org/10.2165/00023210-200721010-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00023210-200721010-00005

Keywords

Search

Navigation